Natural Product Sciences

The Korean Society of Pharmacognosy (한국생약학회)
권호 표지

Hesperidin Improves the IL-6-Mediated Hepatic Insulin Resistance in Hepa-1c1c7 Cells

  • Received : 2012.08.24
  • Accepted : 2012.10.24
  • Published : 2012.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Hesperidin (HES) is a bioflavonoid with antioxidant, anti-inflammatory and anti-diabetic properties. IL-6 is well known as a primary proinflammatory cytokine that contributes to impaired insulin signaling in liver. This study was to investigate whether HES improves IL-6-mediated impairment of insulin sensitivity in liver. Hepa-1c1c7 cells were pre-treated with 50 and $100{\mu}M$ HES in complete media for 1 h and then cultured in the presence or absence of IL-6 (20 ng/ml). These results demonstrated that HES restored IL-6-suppressed expression of IRS-1 protein, downregulated IL-6-increased expression of CRP and SOCS-3 mRNA, and inhibited LPS-induced production of IL-6 in Hepa-1c1c7 cells. These findings indicate that HES may ameliorate hepatic insulin resistance via improvement of IL-6-mediated impaired insulin signaling in hepatocytes.

Keywords

References

  1. Akiyama, S., Katsumata, S., Suzuki, K., Ishimi, Y., Wu, J., and Uehara, M., Dietary hesperidin exerts hypoglycemic and hypolipidemic effects in streptozotocin-induced marginal type 1 diabetic rats. J. Clin. Biochem. Nutr. 46(1), 87-92 (2010).
  2. Akiyama, S., Katsumata, S., Suzuki, K., Nakaya, Y., Ishimi, Y., and Uehara, M., Hypoglycemic and hypolipidemic effects of hesperidin and cyclodextrin-clathrated hesperetin in Goto-Kakizaki rats with type 2 diabetes. Biosci. Biotechnol. Biochem. 73(12), 2779-2782 (2009). https://doi.org/10.1271/bbb.90576
  3. Bastard, J.P., Maachi, M., Lagathu, C., Kim, M.J., Caron, M., Vidal, H., Capeau, J., and Feve, B., Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 17(1), 4-12 (2006).
  4. Berg, A.H. and Scherer, P.E., Adipose tissue, inflammation, and cardiovascular disease. Circulation Research 96, 939-949 (2005). https://doi.org/10.1161/01.RES.0000163635.62927.34
  5. Chen, M., Gu, H., Ye, Y., Lin, B., Sun, L., Deng, W., Zhang, J., and Liu, J., Protective effects of hesperidin against oxidative stress of tert-butyl hydroperoxide in human hepatocytes. Food Chem. Toxicol. 48(10), 2980-2987 (2010). https://doi.org/10.1016/j.fct.2010.07.037
  6. Emanuelli, B., Peraldi, P., Filloux, C., Sawka-Verhelle, D., Hilton, D., and Van Obberghen, E., SOCS-3 is an insulin-induced negative regulator of insulin signaling. J. Biol. Chem. 275, 15985-15991 (2000). https://doi.org/10.1074/jbc.275.21.15985
  7. Fain, J.N., Madan, A.K., Hiler, M.L., Cheema, P., and Bahouth, S.W., Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145(5), 2273-2282 (2004). https://doi.org/10.1210/en.2003-1336
  8. Fontana, L., Eagon, J.C., Trujillo, M.E., Scherer, P.E., and Klein, S., Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 56(4), 1010-1013 (2007). https://doi.org/10.2337/db06-1656
  9. Ganapathi, M.K., Rzewnicki, D., Samols, D., Jiang, S.L., and Kushner, I., Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells. J. Immunol. 147(4), 1261-1265 (1991).
  10. Garg, A., Garg, S., Zaneveld, L.J., and Singla, A.K., Chemistry and pharmacology of the citrus bioflavonoid hesperidin. Phytother. Res. 15(8), 655-669 (2001). https://doi.org/10.1002/ptr.1074
  11. Jain, M. and Parmar, H.S., Evaluation of antioxidative and antiinflammatory potential of hesperidin and naringin on the rat air pouch model of inflammation. Inflamm. Res. 60(5), 483-491 (2011). https://doi.org/10.1007/s00011-010-0295-0
  12. Jung, U.J., Lee, M.K., Park, Y.B., Kang, M.A., and Choi, M.S., Effect of citrus flavonoids on lipid metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice. Int. J. Biochem. Cell. Biol. 38(7), 1134-1145 (2006). https://doi.org/10.1016/j.biocel.2005.12.002
  13. Kamaraj, S., Ramakrishnan, G., Anandakumar, P., Jagan, S., and Devaki, T., Antioxidant and anticancer efficacy of hesperidin in benzo(a) pyrene induced lung carcinogenesis in mice. Invest. New Drugs 27(3), 214-222 (2009). https://doi.org/10.1007/s10637-008-9159-7
  14. Kaptein, A., Paillard, V., and Saunders, M., Dominant negative STAT3 mutant inhibits interleukin-6 induced Jak-STAT signal transduction. J. Biol. Chem. 271, 5961-5964. (1996). https://doi.org/10.1074/jbc.271.11.5961
  15. Kaur, G., Tirkey, N., and Chopra, K., Beneficial effect of hesperidin on lipopolysaccharide-induced hepatotoxicity. Toxicology 226(2-3), 152-160 (2006). https://doi.org/10.1016/j.tox.2006.06.018
  16. Kim, H.J., Higashimori, T., Park, S.Y., Choi, H., Dong, J., Kim, Y.J., Noh, H.L., Cho, Y.R., Cline, G., Kim, J.H., Bachmann, R.A., and Chen, J., Interleukin-6 and insulin resistance. Vitam. Horm. 80, 613-633 (2009).
  17. Klover, P.J., Clementi, A.H., and Mooney, R.A., Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146(8), 3417-3427 (2005). https://doi.org/10.1210/en.2004-1468
  18. Klover, P.J., Zimmers, T.A., Koniaris, L.G., and Mooney, R.A., Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52, 2784-2789 (2003). https://doi.org/10.2337/diabetes.52.11.2784
  19. Kramer, F., Torzewski, J., Kamenz, J., Veit, K., Hombach, V., Dedio, J., and Ivashchenko, Y., Interleukin-1beta stimulates acute phase response and C-reactive protein synthesis by inducing an NFkappaBand C/EBPbeta-dependent autocrine interleukin-6 loop. Mol. Immunol. 45(9), 2678-2689 (2008). https://doi.org/10.1016/j.molimm.2007.12.017
  20. Meshkani, R. and Adeli, K., Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin. Biochem. 42(13-14), 1331-1346 (2009). https://doi.org/10.1016/j.clinbiochem.2009.05.018
  21. Pradhan, A.D., Manson, J.E., Rifai, N., Buring, J.E., and Ridker, P.M., Creactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J. Am. Med. Assoc. 286, 327-334 (2001). https://doi.org/10.1001/jama.286.3.327
  22. Ridker, P.M. and Morrow, D.A., C-reactive protein, inflammation, and coronary risk. Cardiol. Clin. 21(3), 315-325 (2003). https://doi.org/10.1016/S0733-8651(03)00079-1
  23. Saad, B., Frei, K., Schol, F.A., Fontana, A., and Maier, P., Hepatocytederived interleukin-6 and tumor-necrosis factor alpha mediate the lipopolysaccharide-induced acute-phase response and nitric oxide release by cultured rat hepatocytes. Eur. J. Biochem. 229(2), 349-355 (1995). https://doi.org/10.1111/j.1432-1033.1995.0349k.x
  24. Senn, J.J., Klover, P.J., Nowak, I.A., and Mooney, R.A., Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51, 3391-3399 (2002). https://doi.org/10.2337/diabetes.51.12.3391
  25. Senn, J.J., Klover, P.J., Nowak, I.A., Zimmers, T.A., Koniaris, L.G., Furlanetto, R.W., and Mooney, R.A., Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J. Biol. Chem. 278, 13740-13746 (2003). https://doi.org/10.1074/jbc.M210689200
  26. Ueki, K., Kondo, T., and Kahn, C.R., Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol. Cell. Biol. 24, 5434-5446 (2004). https://doi.org/10.1128/MCB.24.12.5434-5446.2004
  27. Xi, L., Xiao, C., Bandsma, R.H., Naples, M., Adeli, K., and Lewis, G.F., C-reactive protein impairs hepatic insulin sensitivity and insulin signaling in rats: Role of mitogen-activated protein kinases. Hepatology 53(1), 127-135 (2011). https://doi.org/10.1002/hep.24011
  28. Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., Sole, J., Nichols, A., Ross, J.S., Tartaglia, L.A., and Chen, H., Chronic inflammation in fat plays a crucial role in the development of obesityrelated insulin resistance. J. Clin. Invest. 112, 1821-1830 (2003).
  29. Yeh, C.C., Kao, S.J., Lin, C.C., Wang, S.D., Liu, C.J., and Kao, S.T., The immunomodulation of endotoxin-induced acute lung injury by hesperidin in vivo and in vitro. Life Sci. 80(20), 1821-1831 (2007). https://doi.org/10.1016/j.lfs.2007.01.052
  30. Zhang, D., Sun, M., Samols, D., and Kushner, I., STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J. Biol. Chem. 271(16), 9503-9509 (1996). https://doi.org/10.1074/jbc.271.16.9503
  31. Zhou, J., Wang, Q., Wang, Q., and Duan, W., Effects of norcantharidin on lipopolysaccharide-induced hepatocyte injury in vitro. Zhong Nan Da Xue Xue Bao Yi Xue Ban 37(3), 285-289 (2012).